Selected Quarterly Financial Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended																12 Months Ended
	Dec. 31, 2016	[1]	Sep. 30, 2016	[1]	Jun. 30, 2016	[1]	Mar. 31, 2016	[1]	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
Selected Quarterly Financial Information [Abstract]
REVENUE	$ 45,029		$ 45,252		$ 47,083		$ 43,016		$ 39,838	$ 36,703	$ 35,526	$ 33,831	$ 37,151	$ 37,069	$ 34,690	$ 35,731	$ 180,380		$ 145,898		$ 144,641
GROSS MARGIN	31,195		29,782		30,301		27,621		26,516	22,982	21,554	19,667	22,635	23,799	22,384	22,473	118,899		90,719		91,291
NET INCOME (LOSS)	$ 2,897		$ 2,993		$ 2,347		$ 2,541		$ 2,636	$ 2,145	$ (502)	$ (274)	$ 1,776	$ 2,326	$ 2,161	$ 1,059	$ 10,778		$ 4,005		$ 7,322
INCOME (LOSS) PER COMMON SHARE - DILUTED	$ 0.09		$ 0.09		$ 0.07		$ 0.08		$ 0.09	$ 0.07	$ (0.02)	$ (0.01)	$ 0.06	$ 0.08	$ 0.08	$ 0.04	$ 0.32	[2]	$ 0.14	[2]	$ 0.25	[2]
Gain on sale of Medafor investment																			$ 891		$ 530

[1] In January 2016 the Company completed its acquisition of On-X Life Technologies Holdings, Inc., which is being operated as a wholly owned subsidiary of CryoLife. In 2016 the Company also sold its HeRO Graft product line and its ProCol product line, and ceased sales of these products during 2016.

[2] The Company excluded stock options from the calculation of diluted weighted-average common shares outstanding if the per share value, including the sum of (i) the exercise price of the options and (ii) the amount of the compensation cost attributed to future services and not yet recognized, was greater than the average market price of the shares, because the inclusion of these stock options would be antidilutive to income per common share. Accordingly, stock options to purchase 1,000, 710,000, and 335,000 shares for the years ended December 31, 2016, 2015, and 2014, respectively, were excluded from the calculation of diluted weighted-average common shares outstanding.